Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Effect of glicentin-related peptides on glucagon secretion in anaesthetized dogs


Recent studies have demonstrated that glicentin is released during nutrient ingestion. However, the biological function of glicentin remains unclear. In order to clarify the role of glicentin in the enteroinsular axis, the effect of glicentin-related peptides was investigated using in vivo local circulation of canine pancreas. Peaks I and II of gut glucagon-like immunoreactivity, partially purified from porcine intestinal extract by affinity chromatography and gel filtration, synthesized hexadecapeptide of N-terminal glicentin (1–16) and synthesized octapeptide of C-terminal glicentin (62–69) were administered for 10 min into the pancreaticoduodenal artery of canine pancreas. Blood samples were then drawn from the pancreaticoduodenal vein. The administration of peak I of glucagon-like immunoreactivity during arginine infusion in a dosage of 20 ng reduced the glucagon secretion by 42 pmol/1 (p<0.05), whereas peak 11 of glucagon-like immunoreactivity (20 ng) slightly increased the plasma level of insulin, although not significantly. The administration of glicentin (1–16) in a dosage of 400 ng during saline infusion did not alter the plasma insulin level, but reduced the plasma glucagon level in the pancreaticoduodenal vein by 29 pmol/1 (p<0.05). In addition, glicentin [62–691 in a dosage of 400 ng exerted a decrease in both the plasma insulin (40 mU/1,p<0.05) and glucagon level (27 pmol/l,p<0.05). The present study demonstrates the suppression of pancreatic glucagon release during the infusion of peak I glucagon-like immunoreactivity and N- or C-terminal glicentin-related peptide. Therefore, it is suggested that glicentin released during nutrient intake might inhibit the secretion of glucagon.


  1. 1.

    Thim L, Moody AJ (1981) The primary structure of porcine glicentin (proglucagon). Regul Peptides 2: 139–150

  2. 2.

    Moody AJ, Holst JJ, Thim L, Jensen SL (1981) Relationship of glicentin to proglucagon and glucagon in the porcine pancreas. Nature 289: 515–516

  3. 3.

    Bell GI, Santerre RF, Mullenbach GT (1983) Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302: 716–718

  4. 4.

    Ohneda A (1985) Response of circulating glicentin to intraduodenal administration of glucose in piglets. J Jap Diab Soc 28: 370 (Japanese)

  5. 5.

    Ohneda A, Tsuchiya T, Naito H, Imamura M, Sasaki I (1986) Response of glicentin secretion to intraluminal administration of fat. Proceedings of the Fourth Gut Hormone Conference. Japanese Society of Gut Hormones, pp 356–360 (Japanese)

  6. 6.

    Glass GBJ (1980) Gastrointestinal hormones, 1st edn. Raven Press, New York, pp 769–829

  7. 7.

    Murphy RF, Buchanan KD, Elmore DT (1973) Isolation of glucagon-like immunoreactivity of gut by affinity chromatography on antiglucagon antibodies coupled to sepharose 4B. Biochem Biophys Acta 303: 118–127

  8. 8.

    Ohneda A, Horigome K, Kai Y, Itabashi H, Ishii S, Yamagata S (1976) Purification of canine gut glucagon-like immunoreactivity (GLI) and its insulin releasing activity. Horm Metab Res 8: 170–174

  9. 9.

    Kirkegaard P, Moody AJ, Holst JJ, Loud FB, Skov P, Christiansen J (1982) Glicentin inhibits gastric acid secretion in the rat. Nature 297: 156–157

  10. 10.

    Gleeson MH, Bloom SR, Polak JK, Henry K, Dowling RH (1971) Endocrine tumour in kidney affecting small bowell structure, motility, and absorptive function. Gut 12: 773–782

  11. 11.

    Ohneda A, Ishii S, Horigome K, Chiba M, Sakai T, Kai Y, Watanabe K, Yamagata S (1977) Effect of intrapancreatic administration of vasoactive intestinal peptide upon the release of insulin and glucagon in dogs. Horm Metab Res 9: 447–452

  12. 12.

    Morgan CR, Lazarow A (1963) Immunoassay of insulin: Two antibody system. Plasma insulin levels of normal, subdiabetic and diabetic rats. Diabetes 12: 115–126

  13. 13.

    Ohneda A, Ishii S, Horigome K, Yamagata S (1975) Glucagon response to arginine after treatment of diabetes mellitus. Diabetes 24: 811–819

  14. 14.

    Teller JD (1956) Direct, quantitative colorimetric determination of serum or plasma glucose. Abstracts of 130th Meeting the American Chemical Society, p69c

  15. 15.

    Moody AJ, Thim L, Holst JJ, Jensen SL (1980) Porcine pancreatic glicentin-related peptide (GRP). Diabetologia 19: 300 (Abstract)

  16. 16.

    Bataille D, Gespach C, Tatemoto K, Marie JC, Coudray AM, Rosselin G, Mutt V (1981) Bioactive enteroglucagon (oxyntomodulin): Present knowledge on its chemical structure and its biological activities. Peptides 2 (Suppl 2): 41–44

  17. 17.

    Kawai K, Unger RH (1982) Inhibition of glucagon secretion by exogenous glucagon in the isolated perfused dog pancreas. Diabetes 31: 512–515

  18. 18.

    Holst JJ (1982) Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33–69) of glicentin. Biochem J207: 381–388

  19. 19.

    Rehfeld JF, Heding LG, Holst JJ (1973) Increased gut glucagon release as pathogenetic factor in reactive hypoglycemia? Lancet 1: 116–118

  20. 20.

    Moody AJ, Jacobsen H, Sundby F (1980) Possible function of intestinal glucagon-like immunoreactance. In: Creutzfeldt W (ed) Frontiers of hormone research. The enteroinsular axis. Karger, Basel, pp 155–163

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ohneda, A., Kobayashi, T. & Nihei, J. Effect of glicentin-related peptides on glucagon secretion in anaesthetized dogs. Diabetologia 29, 397–401 (1986). https://doi.org/10.1007/BF00903352

Download citation

Key words

  • GLI
  • glicentin-related peptide
  • glucagon
  • insulin
  • dog pancreas